Wed, Oct 1, 2014, 1:02 AM EDT - U.S. Markets open in 8 hrs 28 mins


% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • biotechchaser8 biotechchaser8 Feb 15, 2013 10:40 AM Flag

    Three things bother me about GALE

    Number one, too much hype on this board. We have too many full time pumpers here which is usually indicative of a top not a bottom. Number two, very light institutional sponsorship. Number 3, the false identities that were pumping on Seeking Alpha.

    Sentiment: Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Biochaser: I like your post since agree with your concerns. The approach i take is technical analysis and right now we are more likely than not to retrace from the current pps. Below 1.73 is a buy for me but I am not in until we dip below this pps. I made 3k plus since it dipped to 1.5. Not a fortune but it is profit.

      Aim small hit small.

    • biochaser. Your instincts are good. Only amateurs get involved will penny junk.

      Sentiment: Strong Sell

    • what the he** do you think a MB is for? We are not professionals expected to be held to a higher standard. In fact, watch addtion to GALE I like ATHX, PBIO, and WEN at this point

      Sentiment: Strong Buy

    • NeuVax's purpose is to prevent the recurrence of breast cancer, and in December the company announced final results for its Phase II trial that showed only 5.6% of patients' cancer recurred when treated with NeuVax, compared to 25.9% of those who were not vaccinated. Now, we await interim Phase III results in 2013, and there are three factors that give Galena a high probability of success, which could also lead the stock to becoming one of the best investments ever:

      NeuVax was used to treat both node-positive and node-negative patients in its Phase II trial. However, in the Phase III PRESENT trial it will only be tested on node-positive patients. NeuVax was much more efficient on this patient population. For this reason, the Phase III trial is built around the strengths of the vaccine and the results could actually be better than in its Phase II trial.
      All of the patients in the Phase III trial will be optimally dosed. In the Phase II trial only one-third of patients were optimally dosed. This was because the folks at Galena were still trying to determine the best way of using the vaccine. After sorting through the results, Galena and the FDA found an optimal dosing level and determined that all patients in the Phase III trial should be dosed with the most efficient level of NeuVax; or the one that showed the best response.
      All patients will receive booster shots of NeuVax. These boosters have shown a meaningful impact at preventing recurrence as a long-term treatment, and will be incorporated into the Phase III trial. It should be noted that only half of the Phase II patients received booster shots.

    • Once again you can't dispute the data which points to the likely success of Neuvax. Supporters post verifiable evidence and bashers never support their claims. I challenge you to post just one fact against the phase 2 data.

2.06-0.05(-2.37%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Cyber-Ark Software Ltd.
NasdaqGSTue, Sep 30, 2014 4:00 PM EDT
eBay Inc.
NasdaqGSTue, Sep 30, 2014 4:15 PM EDT
Move, Inc.
NasdaqGSTue, Sep 30, 2014 4:00 PM EDT